Shenzhen New Industries Biomedical (300832) — Working Capital to Net Assets Ratio
Shenzhen New Industries Biomedical (300832) has a Working Capital to Net Assets ratio of 51.7% as of September 2025. Working capital of CN¥4.52 Billion (current assets of CN¥5.20 Billion minus current liabilities of CN¥680.50 Million) is measured against net assets of CN¥8.74 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Shenzhen New Industries Biomedical free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shenzhen New Industries Biomedical Working Capital to Net Assets (2012–2024)
This chart shows how Shenzhen New Industries Biomedical's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of September 2025, the ratio stands at 51.7%, reflecting working capital of CN¥4.52 Billion against net assets of CN¥8.74 Billion CNY. See 300832 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Shenzhen New Industries Biomedical (2012–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shenzhen New Industries Biomedical from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market cap of Shenzhen New Industries Biomedical.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 48.4% | CN¥4.15 Billion | CN¥8.58 Billion | CN¥5.06 Billion | CN¥908.74 Million | ▼ -10.9 pp |
| 2023 | 59.3% | CN¥4.47 Billion | CN¥7.54 Billion | CN¥5.06 Billion | CN¥591.48 Million | ▼ -6.9 pp |
| 2022 | 66.2% | CN¥4.24 Billion | CN¥6.40 Billion | CN¥4.82 Billion | CN¥583.94 Million | ▼ -4.9 pp |
| 2021 | 71.1% | CN¥3.99 Billion | CN¥5.61 Billion | CN¥4.50 Billion | CN¥507.94 Million | ▼ -4.5 pp |
| 2020 | 75.6% | CN¥3.63 Billion | CN¥4.80 Billion | CN¥4.12 Billion | CN¥492.74 Million | ▲ +6.3 pp |
| 2019 | 69.3% | CN¥2.18 Billion | CN¥3.14 Billion | CN¥2.48 Billion | CN¥308.37 Million | ▲ +1.6 pp |
| 2018 | 67.7% | CN¥1.60 Billion | CN¥2.37 Billion | CN¥1.87 Billion | CN¥264.18 Million | ▲ +0.2 pp |
| 2017 | 67.5% | CN¥1.20 Billion | CN¥1.77 Billion | CN¥1.44 Billion | CN¥239.16 Million | ▼ -6.3 pp |
| 2016 | 73.7% | CN¥1.05 Billion | CN¥1.42 Billion | CN¥1.21 Billion | CN¥159.11 Million | ▲ +8.8 pp |
| 2015 | 64.9% | CN¥664.44 Million | CN¥1.02 Billion | CN¥771.83 Million | CN¥107.39 Million | ▲ +9.6 pp |
| 2014 | 55.3% | CN¥337.63 Million | CN¥610.52 Million | CN¥449.30 Million | CN¥111.67 Million | ▼ -17.3 pp |
| 2013 | 72.6% | CN¥274.91 Million | CN¥378.84 Million | CN¥358.46 Million | CN¥83.55 Million | ▼ -25.6 pp |
| 2012 | 98.2% | CN¥243.67 Million | CN¥248.18 Million | CN¥289.66 Million | CN¥45.99 Million | — |